Repository logo
 

GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis.

Accepted version
Peer-reviewed

Change log

Authors

Ong, Ken K 

Abstract

Pharmacological options for management of obesity and type 2 diabetes mellitus (T2DM) in children are limited. We aimed to synthesize published randomized controlled trial (RCT) evidence on the efficacy of glucagon-like peptide-1 (GLP-1) agonists in T2DM, pre-diabetes, and obesity in children aged <18 years. Inclusion criteria were RCTs of any GLP-1 agonist, solely or in conjunction with other drugs, for the treatment of obesity, pre-diabetes, and/or T2DM in children aged <18 years old. Nine studies met the inclusion criteria (two for T2DM, one for pre-diabetes, and six for obesity without diabetes). In total, 286 children were allocated to GLP-1 agonist therapy. Compared with controls, GLP-1 agonist therapy reduced HbA1c by -0.30% (95% confidence interval [CI] -0.57, -0.04) with a larger effect in children with (pre-)diabetes (-0.72%; 95% CI -1.17, -0.28; three studies) than in children with obesity (-0.08%; 95% CI -0.13, -0.02; four studies). Conversely, GLP-1 agonist therapy reduced body weight more in children with obesity (-2.74 kg; 95% CI -3.77, -1.70; six studies) than in children with T2DM (-0.97 kg; 95% CI -2.01, 0.08; two studies). Adverse effects included gastrointestinal symptoms and minor hypoglycemic episodes, but not severe hypoglycemia. GLP-1 agonists are efficacious in treating children with obesity and/or T2DM. Effect sizes are comparable with those reported in adults.

Description

Keywords

glucagon-like peptide-1, obesity, pediatric, type 2 diabetes, Adolescent, Child, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents, Pediatric Obesity, Randomized Controlled Trials as Topic

Journal Title

Obes Rev

Conference Name

Journal ISSN

1467-7881
1467-789X

Volume Title

22

Publisher

Wiley

Rights

All rights reserved
Sponsorship
Medical Research Council (MC_UU_12015/2)
MRC (MC_UU_00006/2)
TSC and KKO are supported by the Medical Research Council (Unit programme MC_UU_12015/2)